The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Italy's Draghi says will take AstraZeneca shot, approves new spending plan

Fri, 19th Mar 2021 21:25

* Draghi confident AstraZeneca suspension won't hurt vaccine
drive

* Presents 32-bln euro stimulus package

* Extends ban on firing

* Says now is not the time to worry about rising debt
(Recasts after cabinet meeting, Draghi news conference)

By Giuseppe Fonte and Gavin Jones

ROME, March 19 (Reuters) - Italian Prime Minister Mario
Draghi said on Friday he would personally take the AstraZeneca
COVID-19 vaccine but defended this week's temporary
suspension over concerns about possible side effects.

Italy resumed use of the Anglo-Swedish vaccine on Friday
following a green light from Europe's medicines watchdog EMA,
after a three day pause due to fears about possible blood
clotting.

"Yes, I will take AstraZeneca," the 73-year-old former
European Central Bank chief said at his first news conference
since taking office last month.

"Was it a mistake to suspend the vaccine? No," he said,
adding that it was the government's duty to take the step after
the health issues had emerged in some countries.

Speaking after his cabinet approved some 32 billion euros
($38.09 billion) of stimulus measures to support the battered
economy, Draghi said he was convinced that any reluctance of
Italians to take the vaccine would only be temporary.

The new spending decree, which was already budgeted for by
the previous government led by Giuseppe Conte that collapsed in
January, finances furlough schemes and grants to businesses
forced to close by coronavirus lockdowns.

"The aim is to give as much money as possible to as many
people as possible as quickly as possible," Draghi said, adding
"now is not the time" to worry about Italy's rising public debt,
proportionally the second highest in the euro zone.

The decree increases benefits for the unemployed and
provides fresh financing for the health service as Italian
hospitals grapple with a steady rise in coronavirus infections.

The government also extended a freeze on firing which was
due to expire on March 31. For large businesses which have
access to furlough schemes the extension runs until end-June,
while for small firms it continues through October.

The firing ban was introduced last year to prevent a surge
in unemployment while companies and shops were shuttered to stem
COVID-19.

MORE STIMULUS COMING

Part of the 32-billion euro stimulus will be used to extend
temporary layoff schemes for 13 weeks, rising to up to 28 weeks
for companies which have no access to ordinary social safety
nets, a draft of the decree seen by Reuters showed.

Including the latest measures, Italy has approved almost 200
billion euros of extra spending since the COVID pandemic hit the
country almost 13 months ago.

With most of the country under strict lockdown restrictions,
Draghi has promised more stimulus in April, which a Treasury
official said would push the budget deficit close to 10% of
gross domestic product, up from 9.5% last year.

Rome's public debt stood at a post-war high of 155.6% at the
end of last year.

The economy shrank 8.9% in 2020, Italy's steepest post-war
recession. It is officially forecast to rebound by 6% this year,
but Draghi is expected to cut that goal significantly when Rome
issues new economic forecasts next month.

Of the 32 billion euros approved on Friday, just over 11
billion will fund grants to companies, while some 2.8 billion
euros will go to the health service, mainly to try to accelerate
Italy's sluggish vaccine roll-out.

The most contentious measure is an amnesty on tax arrears
which created tensions in the ruling coalition. Draghi gave few
details on this measure but according to the draft seen by
Reuters it applies to sums of up to 5,000 euros which the
authorities claimed for the period prior to 2011.

It is only available to people with an annual income of
below 30,000 euros.

($1 = 0.8401 euros)
(additional reporting by Angelo Amante, writing by Gavin Jones)

More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.